Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Hematopoietic stem cell transplant (HSCT) is a procedure where healthy hematopoietic stem cells are given to patients with dysfunctional or depleted bone marrow. HSCT therapy is used for both malignant (Acute myeloid leukemia, Myelodysplastic syndromes, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Myeloproliferative disorders, Non-Hodgkin’s lymphoma, Multiple myeloma, Chronic lymphocytic leukemia, Hodgkin’s disease, Juvenile chronic myeloid leukemia)and non-malignant (Aplastic anemia, Paroxysmal nocturnal hemoglobinuria, Fanconi’s anemia, Blackfan-Diamond anemia, Thalassemia major, Sickle cell anemia, Severe combined immunodeficiency, Wiskott-Aldrich syndrome and Inborn errors of metabolism) diseases. In allogeneic hematopoietic stem cell transplantation (HSCT), the stem cells are sourced from a donor different from the recipient. Typically, the donor and recipient share a degree of genetic compatibility known as HLA (human leukocyte antigen) matching, determined by the genes found on chromosome 6. Each individual inherits a set of MHC (major histocompatibility complex) alleles, forming HLA pairs. Crucial HLA loci include HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ. The selection of a donor for allogeneic HSCT considers several factors, including the patient's specific disease, disease stage, and the urgency of finding a suitable donor. In cases where allogeneic HSCT is being contemplated, having a fully HLA-matched sibling as the donor is the preferred choice. This preference is due to the lower risk of graft rejection and graft-versus-host disease (GvHD) when using allogeneic stem cells from a fully HLA-matched sibling. Stem cells can be obtained from three sources:

·       Bone Marrow: This involves a surgical procedure using hollow needles to extract liquid bone marrow from the hip bones. Anticoagulants are added to prevent clumping, and sterile filters remove impurities. Bone marrow can be stored at room temperature, in a refrigerator for a limited time, or cryopreserved for longer storage.

·       Peripheral Blood Progenitor Cells (PBPCs): PBPCs containing HPCs are collected from peripheral blood using an apheresis device. A growth factor is usually administered before collection. Autologous PBPC donors may receive chemotherapy. PBPCs can be stored at room temperature, in refrigerators, or cryopreserved like bone marrow.

·       Umbilical Cord Blood (UCB): UCB, once considered waste, is collected safely after childbirth. Further processing removes red blood cells, which are cryopreserved for future use. UCB can be stored privately or publicly for unrelated recipients.

·       Complications following a bone marrow transplant can be acute or chronic and are influenced by various factors, including age, performance status, stem cell source, and preparative regimen. Acute complications occur within the first 90 days, including myelosuppression, sinusoidal obstruction syndrome, mucositis, graft-versus-host disease, bacterial and viral infections, and fungal infections. Chronic complications encompass chronic GVHD, infections with encapsulated bacteria, and varicella-zoster virus reactivation. The number of allogeneic HCTs performed in the USA increased compared to autologous HCTs. The most common type of allogeneic HCT was from an unrelated donor, followed by transplants from a related donor.

Thelansis’s “Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032